Details for New Drug Application (NDA): 208079
✉ Email this page to a colleague
NDA 208079 describes SERNIVO, which is a drug marketed by Primus Pharms and is included in one NDA. There are seven patents protecting this drug and one Paragraph IV challenge. Additional details are available on the SERNIVO profile page.
The generic ingredient in SERNIVO is betamethasone dipropionate. There are sixty-six drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the betamethasone dipropionate profile page.
The generic ingredient in SERNIVO is betamethasone dipropionate. There are sixty-six drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the betamethasone dipropionate profile page.
Summary for 208079
| Tradename: | SERNIVO |
| Applicant: | Primus Pharms |
| Ingredient: | betamethasone dipropionate |
| Patents: | 7 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SPRAY;TOPICAL | Strength | EQ 0.05% BASE/SPRAY | ||||
| Approval Date: | Feb 5, 2016 | TE: | RLD: | Yes | |||||
| Patent: | 10,179,137 | Patent Expiration: | Aug 31, 2030 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patented Use: | TREATMENT OF PLAQUE PSORIASIS | ||||||||
| Patent: | 9,364,485 | Patent Expiration: | Aug 31, 2030 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patented Use: | TREATMENT OF PLAQUE PSORIASIS | ||||||||
| Patent: | 9,433,630 | Patent Expiration: | Aug 31, 2030 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patented Use: | TREATMENT OF PLAQUE PSORIASIS | ||||||||
Complete Access Available with Subscription
